1. Scrip
  2. >>Focus On Asia
  3. >>Japan

US venture Acucela looks east for $125m IPO

 
• By Ian Haydock

Acucela, a US venture specializing in ophthalmic disorders, is planning to raise up to $125m in an initial public offering in Tokyo to support the development and commercialization of its pipeline.

Acucela, a US venture specializing in ophthalmic disorders, is planning to raise up to $125m in an initial public offering in Tokyo to support the development and commercialization of its pipeline.

Although based in Seattle, Washington, the firm has unusually applied for a listing on the Mothers market for high-tech startups of the Tokyo Stock Exchange

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.